AR111236A1 - Uso intradialítico de tiosulfato de sodio - Google Patents

Uso intradialítico de tiosulfato de sodio

Info

Publication number
AR111236A1
AR111236A1 ARP180100530A ARP180100530A AR111236A1 AR 111236 A1 AR111236 A1 AR 111236A1 AR P180100530 A ARP180100530 A AR P180100530A AR P180100530 A ARP180100530 A AR P180100530A AR 111236 A1 AR111236 A1 AR 111236A1
Authority
AR
Argentina
Prior art keywords
intradialitical
tiosulfate
sodium
sodium tiosulfate
methods
Prior art date
Application number
ARP180100530A
Other languages
English (en)
Spanish (es)
Inventor
Craig Sherman
Original Assignee
Hope Medical Entpr Inc Dba Hope Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hope Medical Entpr Inc Dba Hope Pharmaceuticals filed Critical Hope Medical Entpr Inc Dba Hope Pharmaceuticals
Publication of AR111236A1 publication Critical patent/AR111236A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
    • A61M1/16—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
    • A61M1/1654—Dialysates therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
    • A61M1/16—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
    • A61M1/1654—Dialysates therefor
    • A61M1/1656—Apparatus for preparing dialysates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Anesthesiology (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • External Artificial Organs (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ARP180100530A 2017-03-08 2018-03-07 Uso intradialítico de tiosulfato de sodio AR111236A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762468871P 2017-03-08 2017-03-08

Publications (1)

Publication Number Publication Date
AR111236A1 true AR111236A1 (es) 2019-06-19

Family

ID=63446695

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180100530A AR111236A1 (es) 2017-03-08 2018-03-07 Uso intradialítico de tiosulfato de sodio

Country Status (15)

Country Link
US (5) US10744156B2 (enExample)
EP (2) EP3592824B1 (enExample)
JP (3) JP7416622B2 (enExample)
KR (4) KR102758644B1 (enExample)
AR (1) AR111236A1 (enExample)
AU (2) AU2018231072B2 (enExample)
BR (1) BR112019018646A2 (enExample)
CA (1) CA3055107A1 (enExample)
ES (1) ES2992792T3 (enExample)
IL (4) IL302827B2 (enExample)
NZ (1) NZ756704A (enExample)
PH (1) PH12019501971A1 (enExample)
TW (3) TWI789378B (enExample)
WO (1) WO2018165108A1 (enExample)
ZA (2) ZA202105781B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2992792T3 (en) 2017-03-08 2024-12-18 Hope Medical Entpr Inc D B A Hope Pharmaceuticals Intradialytic use of sodium thiosulfate
MD3817751T2 (ro) 2018-07-03 2025-10-31 Fennec Pharmaceuticals Inc Compoziții de tiosulfat de sodiu anhidru
US11850313B2 (en) * 2019-12-20 2023-12-26 The London Health Sciences Centre Research Inc. Method and compositions for protecting tissue
WO2024092228A2 (en) * 2022-10-28 2024-05-02 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Localized delivery of sodium thiosulfate nanoparticles to mitigate arterial calcification
CN116573782B (zh) * 2023-04-03 2023-11-03 迁安市宏奥工贸有限公司 脱硫废液的处理方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1341151C (en) 1985-09-10 2000-12-05 Elias Klein Osmotic agents form peritoneal dialysis
US5108767A (en) * 1991-06-10 1992-04-28 Abbott Laboratories Liquid nutritional product for persons receiving renal dialysis
US6380163B1 (en) 1992-12-22 2002-04-30 Baxter International Inc. Peritoneal dialysis solutions with polypeptides
FI98538C (fi) * 1993-10-20 1997-07-10 Enso Gutzeit Oy Menetelmä natriumhydroksidin valmistamiseksi valkolipeästä
US6306836B1 (en) 1994-01-21 2001-10-23 Baxter International Inc. Peritoneal dialysis solutions containing maltodextrins and amino acids
US6436969B1 (en) 1995-09-12 2002-08-20 Kansas University Medical Center Research Institute Inc. Dialysis solutions and methods
CA2422850C (en) * 1999-09-22 2009-03-03 Advanced Renal Technologies High citrate dialysate and uses thereof
CA2406081C (en) * 2000-04-26 2009-12-22 Oregon Health Sciences University Administration of a thiol-based chemoprotectant compound
JP4882054B2 (ja) 2000-09-13 2012-02-22 独立行政法人科学技術振興機構 腹膜透析液およびその調製法
CA2537222A1 (en) 2003-07-09 2005-01-27 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of nitrite salts for the treatment of cardiovascular conditions
WO2006001345A1 (ja) 2004-06-23 2006-01-05 Kyowa Hakko Kogyo Co., Ltd. Ｌ－リジン・クエン酸塩結晶
US20070154570A1 (en) 2004-09-29 2007-07-05 Miller Christopher C Use of nitric oxide in the treatment and disinfection of biofilms
US7834065B2 (en) 2005-01-31 2010-11-16 Bmg Incorporated Medical-use two part reactive adhesive and medical-use resin having self-degradation property
US20090304600A1 (en) * 2008-06-09 2009-12-10 Anupkumar Shetty Intradialytic administration of sodium thiosulfate
US8568793B2 (en) 2009-02-11 2013-10-29 Hope Medical Enterprises, Inc. Sodium nitrite-containing pharmaceutical compositions
DK2451435T4 (da) 2009-07-08 2022-02-28 Hope Medical Entpr Inc D B A Hope Pharmaceuticals Natriumthiosulfat-indeholdende farmaceutiske sammensætninger
WO2013023217A1 (en) 2011-08-11 2013-02-14 Board Of Regents, The University Of Texas System Method of measuring and monitoring in vivo nitrite levels
AU2013212264B2 (en) 2012-01-23 2017-05-18 Santalis Pharmaceuticals Inc. Sandalwood oil and its uses related to clostridium infections
JP2015516407A (ja) * 2012-05-10 2015-06-11 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 異所性石灰化の治療のためのチオ硫酸ナトリウム
JP5486069B1 (ja) * 2012-11-05 2014-05-07 旭 酒井 透析装置
US20140350097A1 (en) 2013-05-23 2014-11-27 Medinox,Inc. Treatment of hypotension associated with hemodialysis
WO2016094409A1 (en) * 2014-12-09 2016-06-16 Villarreal Anna Methods and devices for female health monitoring
ES2992792T3 (en) 2017-03-08 2024-12-18 Hope Medical Entpr Inc D B A Hope Pharmaceuticals Intradialytic use of sodium thiosulfate
IL301302B2 (en) 2017-03-08 2024-09-01 Hope Medical Entpr Inc Dba Hope Pharmaceuticals Intradialytic use of sodium nitrite

Also Published As

Publication number Publication date
CA3055107A1 (en) 2018-09-13
IL302827B1 (en) 2024-06-01
EP3592824A1 (en) 2020-01-15
EP4403215A3 (en) 2024-10-09
KR102758644B1 (ko) 2025-01-23
US20220031735A1 (en) 2022-02-03
IL295119B1 (en) 2023-06-01
AU2024203603A1 (en) 2024-06-20
ZA202209104B (en) 2024-12-18
EP3592824A4 (en) 2020-12-23
IL295119B2 (en) 2023-10-01
KR102706439B1 (ko) 2024-09-19
JP7416622B2 (ja) 2024-01-17
TWI789378B (zh) 2023-01-11
BR112019018646A2 (pt) 2020-04-07
US10744156B2 (en) 2020-08-18
KR20240139090A (ko) 2024-09-20
AU2018231072A1 (en) 2019-09-19
EP4403215A2 (en) 2024-07-24
IL302827B2 (en) 2024-10-01
IL268883A (en) 2019-10-31
TW202517284A (zh) 2025-05-01
KR20190129911A (ko) 2019-11-20
IL268883B (en) 2022-09-01
KR20240038813A (ko) 2024-03-25
AU2018231072B2 (en) 2024-04-04
KR20250007674A (ko) 2025-01-14
IL295119A (en) 2022-09-01
TWI869743B (zh) 2025-01-11
JP2024045164A (ja) 2024-04-02
NZ756704A (en) 2022-07-01
US12370212B2 (en) 2025-07-29
JP7642878B2 (ja) 2025-03-10
JP2025084833A (ja) 2025-06-03
ZA202105781B (en) 2023-05-31
IL312724A (en) 2024-07-01
TW201840343A (zh) 2018-11-16
IL302827A (en) 2023-07-01
TW202315650A (zh) 2023-04-16
JP2020510680A (ja) 2020-04-09
ES2992792T3 (en) 2024-12-18
US20180256639A1 (en) 2018-09-13
PH12019501971A1 (en) 2020-06-15
KR102647836B1 (ko) 2024-03-15
US11779596B2 (en) 2023-10-10
WO2018165108A1 (en) 2018-09-13
US11116790B2 (en) 2021-09-14
US20250332194A1 (en) 2025-10-30
EP3592824B1 (en) 2024-06-12
US20240100086A1 (en) 2024-03-28
US20200338120A1 (en) 2020-10-29

Similar Documents

Publication Publication Date Title
AR111236A1 (es) Uso intradialítico de tiosulfato de sodio
DOP2019000005A (es) 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2
CR20160069A (es) Compuestos terapéuticamente activos y sus métodos de uso
MX2019008208A (es) Métodos para tratar el cáncer con anticuerpos anti-tim-3.
CO2017001994A2 (es) Compuestos activos hacia bromodominios
MX2018003893A (es) Moduladores del receptor p2x3 y p2x2/3 de diaminopirimidina para usarse en el tratamiento de la tos.
SV2015005115A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
MX2014015185A (es) Derivados deuterados de ruxolitinib.
MX2018001723A (es) Conjugados farmaco-multiligando y usos de los mismos.
SV2018005687A (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cancer
JOP20160092B1 (ar) علاج البيتا ثلاسيميا باستخدام مصطبة لجائنية
PE20142363A1 (es) Usos y articulo de fabricacion que incluye el inhibidor de la dimerizacion de her2 pertuzumab
MX386826B (es) Compuestos de triazolopiridina y métodos para el tratamiento de fibrosis cística
NI201500140A (es) Compuestos y composiciones terapéuticos
MX379297B (es) Compuestos alqueno tetrasustituidos y su uso.
MX2017007458A (es) Derivados del factor 21 de crecimiento de fibroblastos (fgf21) y sus usos.
CO2020005919A2 (es) Compuestos y composiciones farmaceuticas de los mismos para usarse en el tratamiento de enfermedades fibroticas
ZA202307367B (en) Intradialytic use of sodium nitrite
AR111374A1 (es) Uso de lik066 en pacientes con insuficiencia cardíaca
EA201790726A1 (ru) Фармацевтическая композиция для лечения язвенного колита
PE20181332A1 (es) Metodos de sedacion y formulacion parenteral para uso durante el tratamiento de cuidados criticos
BR112016029012A2 (pt) método de tratamento de câncer de pulmão de células não pequenas e/ou câncer de pulmão de células pequenas usando compostos de tienotriazolodiazepina
MX2020007760A (es) Composiciones y metodos para mejorar la biodisponibilidad de 5-hidroxitriptofano.
DOP2017000014A (es) Métodos para mejorar el rendimiento miocárdico en pacientes con cirugía de fontan que utilizan composiciones de udenafilo
BR112019009029A2 (pt) anticorpos anti-bag3 em combinação com inibidores do ponto de verificação imune para uso terapeutico

Legal Events

Date Code Title Description
FC Refusal